- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
McKesson to Distribute Future COVID-19 Vaccines in Support of Operation Warp Speed
The CDC is exercising an option of an existing contract with McKesson for this effort.
IRVING, Texas, August 14, 2020—A global leader in the healthcare industry, McKesson Corporation (NYSE: MCK) will expand its existing partnership with the CDC to support the US government’s Operation Warp Speed team as a centralized distributor of future coronavirus disease 2019 (COVID-19) vaccines and ancillary supplies needed to administer vaccinations. Vaccines and related supplies will be delivered to point-of-care sites across the country at the US government’s direction.
“McKesson is committed to supporting public health in the U.S. and around the world,” said Brian Tyler, CEO of McKesson. “Since the onset of the pandemic, McKesson has leveraged our deep expertise to help maintain the integrity of the healthcare supply chain, source and distribute personal protective equipment to frontline workers and stand up COVID-19 testing at Health Mart pharmacies, many in underserved communities. We are honored that the US government has asked McKesson to play a key role in the effort to distribute COVID-19 vaccines.”
Alexander I. Spira, MD, PhD, of The US Oncology Network, discusses findings from the COCOON trial that show prophylactic treatment reduces dermatological adverse events in patients with non–small cell lung cancer (NSCLC), enhancing their quality of life during amivantamab therapy.
Read More
From Red Tape to Relief: Rewriting the Rules of Prior Authorization
June 23rd 2025Up to 257 million Americans could benefit from these prior authorization reforms that could have cross-market implications on health care plans administered through commercial insurers, Medicare Advantage, and Medicaid.
Read More
Many Patients Stop GLP-1s Before Reaching Target Dose: Hamlet Gasoyan, PhD
June 19th 2025Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite provider follow-up and efforts to manage side effects, says Hamlet Gasoyan, PhD, Cleveland Clinic.
Read More
